Butofilolol
From Wikipedia the free encyclopedia
Clinical data | |
---|---|
Other names | CM-6805 |
ATC code |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.055.892 |
Chemical and physical data | |
Formula | C17H26FNO3 |
Molar mass | 311.397 g·mol−1 |
3D model (JSmol) | |
| |
|
Butofilolol (trade name Cafide) is a beta-blocker drug for the treatment of essential hypertension (high blood pressure).[1][2] It is not known to be marketed anywhere.
It is an example of a butyrophenone.
Synthesis
[edit]The Fries rearrangement of the ester formed by 4-fluorophenol (1)[3] and butryryl chloride (2) gives 5'-fluoro-2'-hydroxybutyrophenone (3). Treatment with epichlorohydrin in the presence of base leads to 1-[5-fluoro-2-(oxiranylmethoxy)phenyl]butan-1-one (4). Lastly, reaction with tert-butylamine gives butofilolol.[4][5]
References
[edit]- ^ Houin G, Barre J, Jeanniot JP, Ledudal P, Cautreels W, Tillement JP (1984). "Pharmacokinetics of butofilolol (CAFIDE) after repeated oral administration in man". International Journal of Clinical Pharmacology Research. 4 (3): 175–83. PMID 6149195.
- ^ Toussain P, Gay G, Debry G (June 1983). "[Long-term hypotensive treatment by butofilolol]". Annales de Cardiologie et d'Angeiologie. 32 (4): 277–83. PMID 6412614.
- ^ Mercier C, Youmans P (1996). "4-fluorophenol: A key intermediate for agrochemicals and pharmaceuticals". The Roots of Organic Development. Industrial Chemistry Library. Vol. 8. pp. 293–300. doi:10.1016/S0926-9614(96)80020-7. ISBN 978-0-444-82434-9.
- ^ Castañer J, Neuman M (1982). "Butofilolol". Drugs of the Future. 7 (2): 96. doi:10.1358/dof.1982.007.02.199366.
- ^ US 4252825, Demarne H, "ompositions for treatment of cardiovascular conditions associated with overproduction of catecholamines", issued 24 February 1981, assigned to C. M. Industries)